See more : Lodestar Minerals Limited (LSR.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Avadel Pharmaceuticals plc (AVDL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avadel Pharmaceuticals plc, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Joshua Gold Resources Inc. (JSHG) Income Statement Analysis – Financial Results
- Elanor Investors Group (ENN.AX) Income Statement Analysis – Financial Results
- Kirin Holdings Company, Limited (KNBWF) Income Statement Analysis – Financial Results
- IFGL Refractories Limited (IFGLEXPOR.NS) Income Statement Analysis – Financial Results
- G G Engineering Limited (GGENG.BO) Income Statement Analysis – Financial Results
Avadel Pharmaceuticals plc (AVDL)
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27.96M | 0.00 | 0.00 | 22.33M | 59.22M | 103.27M | 172.74M | 150.25M | 173.21M | 14.78M | 22.44M | 26.10M | 32.60M | 37.09M | 42.12M | 38.62M | 36.65M | 23.02M | 23.60M | 55.41M | 25.17M | 18.41M | 13.09M | 10.90M | 11.04M | 9.52M | 8.10M | 4.90M |
| Cost of Revenue | 846.00K | 1.49M | 815.00K | 5.74M | 12.13M | 17.52M | 16.30M | 13.25M | 10.92M | 3.38M | 4.35M | 5.86M | 6.28M | 6.91M | 10.12M | 9.62M | 17.32M | 6.25M | 2.53M | 3.60M | 3.68M | 2.37M | 2.17M | 1.75M | 2.09M | 3.53M | 3.10M | 400.00K |
| Gross Profit | 27.12M | -1.49M | -815.00K | 16.59M | 47.09M | 85.75M | 156.44M | 137.00M | 162.29M | 11.39M | 18.09M | 20.24M | 26.32M | 30.18M | 32.00M | 29.00M | 19.33M | 16.77M | 21.07M | 51.81M | 21.49M | 16.03M | 10.92M | 9.15M | 8.95M | 5.99M | 5.00M | 4.50M |
| Gross Profit Ratio | 96.97% | 0.00% | 0.00% | 74.29% | 79.52% | 83.04% | 90.56% | 91.18% | 93.69% | 77.10% | 80.62% | 77.55% | 80.72% | 81.36% | 75.98% | 75.09% | 52.75% | 72.85% | 89.30% | 93.50% | 85.39% | 87.11% | 83.45% | 83.95% | 81.10% | 62.90% | 61.73% | 91.84% |
| Research & Development | 13.26M | 20.70M | 17.10M | 20.44M | 32.92M | 39.33M | 34.22M | 34.61M | 25.61M | 17.30M | 26.69M | 26.12M | 25.09M | 28.69M | 30.42M | 36.25M | 43.56M | 38.23M | 47.30M | 35.36M | 20.22M | 12.24M | 10.66M | 9.79M | 11.05M | 10.61M | 10.10M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100.36M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 151.71M | 74.52M | 68.50M | 32.41M | 30.18M | 100.36M | 58.86M | 44.18M | 21.71M | 15.70M | 13.31M | 14.15M | 10.81M | 11.33M | 13.34M | 12.91M | 16.63M | 17.38M | 14.54M | 7.61M | 5.97M | 4.02M | 3.41M | 3.46M | 3.69M | 3.63M | 3.20M | 12.60M |
| Other Expenses | 0.00 | 3.35M | 217.00K | 406.00K | 816.00K | 1.90M | 2.09M | -6.55M | 0.00 | -36.00K | 573.00K | 102.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 164.97M | 95.22M | 85.60M | 53.25M | 63.92M | 146.31M | 96.74M | 92.68M | 59.88M | 44.75M | 39.99M | 40.27M | 35.90M | 40.02M | 43.75M | 49.16M | 60.18M | 55.61M | 61.84M | 42.97M | 26.19M | 16.26M | 14.08M | 25.26M | 15.95M | 15.28M | 14.00M | 13.50M |
| Cost & Expenses | 165.81M | 95.22M | 85.60M | 59.00M | 76.04M | 163.82M | 113.04M | 105.93M | 70.81M | 48.13M | 44.34M | 46.13M | 42.18M | 46.93M | 53.87M | 58.78M | 77.50M | 61.86M | 64.37M | 46.58M | 29.87M | 18.63M | 16.24M | 27.01M | 18.04M | 18.81M | 17.10M | 13.90M |
| Interest Income | 0.00 | 11.12M | 2.13M | 12.59M | 1.07M | 0.00 | 0.00 | 0.00 | 0.00 | 963.00K | 254.00K | 629.00K | 667.00K | 464.00K | 525.00K | 1.43M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 9.89M | 12.34M | 9.94M | 12.99M | 12.48M | 10.62M | 1.05M | 963.00K | 6.30M | 9.27M | 4.35M | 118.00K | 73.00K | 24.00K | 100.00K | 18.00K | 16.00K | 35.00K | 68.00K | 45.00K | 29.00K | 49.00K | 52.00K | 51.00K | 0.00 | 95.00K | 0.00 | 100.00K |
| Depreciation & Amortization | 1.77M | 1.49M | 815.00K | 1.69M | 2.49M | 7.43M | 4.88M | 14.49M | 13.13M | 14.14M | 3.06M | 3.18M | 3.35M | 4.70M | 5.92M | 7.25M | 6.20M | 5.64M | 4.74M | 2.53M | 1.71M | 1.46M | 1.27M | 1.11M | 1.21M | 1.04M | 700.00K | 900.00K |
| EBITDA | -149.13M | -97.60M | -84.78M | -34.97M | -23.61M | -95.15M | 65.89M | 5.73M | 115.54M | -94.74M | -50.03M | -8.36M | -5.16M | -4.05M | -5.42M | -11.30M | -33.22M | -33.20M | -36.03M | 9.34M | -2.99M | 1.24M | -1.89M | -14.99M | -5.79M | -8.25M | -8.30M | -8.10M |
| EBITDA Ratio | -533.29% | 0.00% | 0.00% | -141.52% | -24.22% | -51.44% | 37.39% | 39.14% | 66.70% | -123.76% | -95.02% | -139.41% | -30.64% | -28.24% | -27.64% | -29.72% | -93.83% | -142.19% | -175.99% | 20.77% | -12.30% | -6.47% | -14.82% | -137.98% | -53.73% | -85.84% | -111.11% | -179.59% |
| Operating Income | -137.85M | -98.56M | -85.55M | -36.66M | -16.83M | -104.93M | 88.30M | -4.97M | 71.45M | -93.86M | -50.03M | -3.49M | -9.58M | -9.84M | -11.75M | -20.16M | -40.85M | -38.84M | -40.77M | 8.84M | -4.70M | -223.00K | -3.16M | -16.11M | -7.00M | -9.29M | -9.00M | -9.00M |
| Operating Income Ratio | -492.97% | 0.00% | 0.00% | -164.15% | -28.42% | -101.60% | 51.12% | -3.30% | 41.25% | -635.24% | -222.93% | -13.36% | -29.40% | -26.53% | -27.90% | -52.20% | -111.44% | -168.71% | -172.76% | 15.94% | -18.67% | -1.21% | -24.11% | -147.74% | -63.41% | -97.57% | -111.11% | -183.67% |
| Total Other Income/Expenses | -22.93M | -12.88M | -7.60M | -10.90M | -14.47M | -8.27M | 3.16M | -4.75M | 6.26M | 3.33M | -4.06M | 1.98M | 1.00M | 1.07M | 314.00K | 1.60M | 1.42M | 1.52M | 9.11M | 463.00K | 272.00K | 2.68M | 295.00K | 11.27M | 322.00K | 232.00K | 800.00K | 600.00K |
| Income Before Tax | -160.78M | -111.44M | -93.15M | -5.08M | -38.58M | -113.20M | 91.47M | -9.72M | 78.39M | -90.33M | -54.10M | -7.93M | -8.58M | -8.77M | -11.44M | -18.56M | -39.43M | -37.32M | -31.66M | 9.30M | -4.00M | 2.45M | -2.86M | -4.83M | -6.68M | -9.06M | -8.20M | -8.40M |
| Income Before Tax Ratio | -574.96% | 0.00% | 0.00% | -22.75% | -65.16% | -109.61% | 52.95% | -6.47% | 45.26% | -611.38% | -241.03% | -30.38% | -26.33% | -23.63% | -27.16% | -48.06% | -107.58% | -162.12% | -134.18% | 16.78% | -15.88% | 13.32% | -21.85% | -44.34% | -60.49% | -95.14% | -101.23% | -171.43% |
| Income Tax Expense | -501.00K | 26.03M | -15.82M | -12.11M | -5.36M | -17.89M | 24.22M | 31.56M | 37.74M | -1.41M | -11.17M | -4.70M | 192.00K | 209.00K | -6.23M | -6.48M | -1.69M | -2.12M | -4.29M | -3.20M | -503.00K | -553.00K | 14.00K | 50.00K | 16.00K | -1.25M | -1.40M | -1.50M |
| Net Income | -160.28M | -137.46M | -77.33M | 7.03M | -33.23M | -95.30M | 67.25M | -41.28M | 40.66M | -84.91M | -42.93M | -3.23M | -8.77M | -8.98M | -11.44M | -12.08M | -37.74M | -35.20M | -27.38M | 12.50M | -3.49M | 3.01M | -2.87M | -9.46M | -6.69M | -7.81M | -6.80M | -6.90M |
| Net Income Ratio | -573.17% | 0.00% | 0.00% | 31.47% | -56.11% | -92.29% | 38.93% | -27.47% | 23.47% | -574.66% | -191.26% | -12.37% | -26.91% | -24.20% | -27.16% | -31.29% | -102.95% | -152.91% | -116.01% | 22.56% | -13.88% | 16.33% | -21.96% | -86.78% | -60.63% | -82.04% | -83.95% | -140.82% |
| EPS | -2.00 | -2.29 | -1.32 | 0.13 | -0.89 | -2.55 | 1.66 | -1.00 | 1.00 | -2.34 | -1.69 | -0.13 | -0.36 | -0.37 | -0.47 | -0.50 | -1.57 | -1.48 | -1.19 | 0.58 | -0.20 | 0.19 | -0.18 | -0.62 | -0.52 | -0.65 | -0.65 | -0.80 |
| EPS Diluted | -2.00 | -2.29 | -1.32 | 0.13 | -0.89 | -2.55 | 1.61 | -1.00 | 0.93 | -2.34 | -1.69 | -0.13 | -0.36 | -0.37 | -0.47 | -0.50 | -1.57 | -1.48 | -1.19 | 0.53 | -0.20 | 0.18 | -0.18 | -0.62 | -0.52 | -0.65 | -0.65 | -0.80 |
| Weighted Avg Shares Out | 80.17M | 60.09M | 58.54M | 53.00M | 37.40M | 37.33M | 40.47M | 41.25M | 40.58M | 36.21M | 25.41M | 24.95M | 24.67M | 24.41M | 24.23M | 24.08M | 24.02M | 23.81M | 23.00M | 21.51M | 17.76M | 16.20M | 16.20M | 15.33M | 12.94M | 12.05M | 10.46M | 8.63M |
| Weighted Avg Shares Out (Dil) | 80.17M | 60.09M | 58.54M | 54.94M | 37.40M | 37.33M | 41.77M | 41.25M | 43.62M | 36.21M | 25.45M | 25.09M | 24.67M | 24.41M | 24.23M | 24.08M | 24.02M | 23.81M | 23.00M | 23.56M | 17.76M | 16.71M | 16.20M | 15.33M | 12.94M | 12.05M | 10.46M | 8.63M |
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
DUBLIN, Ireland, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences:
Avadel Pharmaceuticals plc (AVDL) Q3 2022 Earnings Call Transcript
Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q3 2022 Earnings Conference Call November 9, 2022 8:00 AM ET Company Participants Gregory Divis - Chief Executive Officer Jennifer Gudeman - Vice President of Medical & Clinical Affairs Richard Kim - Chief Commercial Officer...
Avadel's LUMRYZ: A Good Night's Sleep For Narcolepsy Patients
Avadel Pharmaceuticals' LUMRYZ (FT218), with its essential once daily dosing, has snagged a tentative approval from the FDA. Once finally approved, LUMRYZ has serious prospects for knocking off Jazz's flawed blockbuster XYREM/XYWAV duopoly.
Avadel Pharmaceuticals: Navigating Through The Uncertainty
Avadel Pharmaceuticals goes into the spotlight today. This small biopharma company recently got 'tentative' FDA approval for its flagship drug but is still waiting on one patent challenge to move forward to commercialization.
Avadel Pharmaceuticals plc (AVDL) CEO Gregory Divis on Q2 2022 Results - Earnings Call Transcript
Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q2 2022 Earnings Conference Call August 9, 2022 8:00 AM ET Company Participants Brandi Robinson - Senior Vice President of Corporate Affairs Gregory Divis - Chief Executive Officer Jennifer Gudeman - Vice President of Medical...
Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter Financial Results on August 9
DUBLIN, Ireland, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:00 a.m. ET on...
Avadel Cuts Workforce, Optimizes Cost Structure To Support This
Avadel Pharmaceuticals plc (NASDAQ: AVDL) announced its steps to explore every available pathway to accelerate the FDA approval of its lead drug candidate, FT218, before June 2023. Avadel has received and agreed upon what is expected to be a final label and is completing.
Avadel: Further Delay, But Some Light At The End Of The Tunnel
AVDL's FT218 is going to get delayed further over a patent issue. However, there's a goalpost in sight now, and the date is June 2023.
How to Make Money With Penny Stocks in June, 3 Tips
What you need to know about trading penny stocks right now The post How to Make Money With Penny Stocks in June, 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Top Penny Stocks Today: What's Moving AVDL, BKSY, NILE, INO, & ALLR
Are these penny stocks to buy or avoid right now? The post Top Penny Stocks Today: What's Moving AVDL, BKSY, NILE, INO, & ALLR appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Source: https://incomestatements.info
Category: Stock Reports